Related Experiment Videos
Hematopoietic growth factors in pediatrics
1Department of Pediatrics, US Naval Hospital, Oakland, CA 94627-5000.
Current Opinion in Pediatrics
|February 1, 1993
Summary
Recombinant hematopoietic growth factors like erythropoietin and colony-stimulating factors are effective in treating anemias and neutrophil disorders. These growth factors show promise for various pediatric and adult conditions, including chronic renal failure and cancer treatment side effects.
Area of Science:
- Biotechnology
- Hematology
- Immunology
Background:
- Hematopoietic growth factors are crucial for blood cell development.
- Recombinant human versions offer therapeutic potential.
Purpose of the Study:
- To review the clinical applications of human recombinant hematopoietic growth factors.
- To highlight their efficacy in various hematological conditions.
Main Methods:
- Review of existing clinical data and therapeutic outcomes.
- Analysis of efficacy in treating anemia and myeloid cell disorders.
Main Results:
- Recombinant human erythropoietin effectively treats anemia in chronic renal failure and premature infants.
- Granulocyte colony-stimulating factors benefit children with neutrophil production disorders and show promise in cancer therapy and HIV infections.
Conclusions:
- Human recombinant hematopoietic growth factors are valuable therapeutic agents.
- They offer significant clinical benefits for anemia, neutropenia, and other hematological conditions across different patient populations.